Navigation Links
CytoFuge 2

ProductsCytoFuge 2
Company Iris Sample Processing (formerly StatSpin, Inc.)
Item CytoFuge 2
Features 
  • Compact and Quiet fits in small area or safety hood
  • Reduces exposure to biohazards with covered rotor and chamber gaskets
  • Optimal control acceleration and braking
  • Cover Interlock System prevents operation with cover open
  • Patented rotor design eliminates trunnion carriers or bulky clamps
  • Accurate and Repeatable speed and cycle time controls accommodate a range of applications
Description The StatSpin CytoFuge 2 is the perfect solution for your cyto- centrifuge needs. It's simple, understandable controls and new snap-seal Filter Concentrators make operation easier than ever before. Samples are processed quickly, silently and conveniently on any bench or in a safety cabinet. Results are consistent: easy to scan monolayer cell presentations of excellent morphologic detail.
Info Iris Sample Processing (formerly StatSpin, Inc.)
Customer Service: (800) STATSPIN (782-8774)
Web site: http://www.statspin.com

Related medicine products :

1. ImmuLisa Anti-Proteinase 3 PR3 (cANCA) Assay
2. ImmuLisa™ anti-gliadin-IgG Kit
3. ImmuLisa™ anti-gliadin(AGA)IgA Kit
4. ImmuLisa Anti-hu tTG IgA ELISA
5. ImmuLisa Anti-Nuclear Antibody (ANA) Screen ELISA
6. ImmuLisa™ IgA-ACA anti-Cardiolipin Antibody (ACA) Kit
7. ImmuLisa™ IgG-ACA anti-Cardiolipin Antibody (ACA) Kit
8. ImmuLisa™ IgM-ACA anti-Cardiolipin Antibody (ACA) Kit
9. ImmuLisa™ anti-2-GP1 IgG Kit
10. ImmuLisa™ anti-2-GP1 IgM Kit
11. ImmuLisa™ Rheumatoid Factor IgA Kit
... an innovative handheld device for ... non-invasively, comfortably, and accurately.,It is, ... than an automatic blood pressure ... charge, Vasotrax will take approximately ...
... Insulin-like growth factor II (IGF-II) is a 7.5 ... liver and is postulated to have mitogenic and ... of IGF-II are mediated by binding to target ... the Type II IGF receptor, a monomeric protein ...
... Pregnancy-associated plasma protein A (PAPP-A) is ... is produced in high concentrations by ... into the maternal circulation in increasing ... PAPP-A is not specific to pregnancy ...
... Pregnancy-associated plasma protein A (PAPP-A) ... PAPP-A is produced in high concentrations ... released into the maternal circulation in ... [1]. PAPP-A is not specific to ...
Medicine Products:
(Date:7/21/2017)... ... July 21, 2017 , ... ... students improve their chances of acceptance to a residency in a United States ... earned degrees outside the U.S. , According to data released by the ECFMG®, ...
(Date:7/21/2017)... ... July 21, 2017 , ... West Dermatology is pleased ... Vu, PA-C. Beginning July 17, 2017, Ms. Vu will join West Dermatology’s large network ... experience in dermatology, skin cancer , and more. She graduated from the University ...
(Date:7/21/2017)... ... July 21, 2017 , ... How physicians and ... the rise, say researchers presenting their work at the American Orthopaedic Society ... combination of evaluating the patterns of change in concussion symptom presentation, diagnostic tools ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia (AML) is ... rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and a stem ... With such a challenging diagnosis that requires immediate action, patients and caregivers ...
(Date:7/20/2017)... ... ... For individuals with extended hospital stays or who are residents of nursing ... specially designed to accommodate patients with a wide range of ailments or special needs, ... has invented the patent-pending PORTABLE ARM REST, a specially designed armrest that features many ...
Breaking Medicine News(10 mins):
(Date:7/12/2017)... and Company (NYSE: LLY ) has entered into ... litigation in the U.S. District Court for the Eastern District ... (tadalafil) unit dose patent. This patent was previously set ... agreement, Cialis exclusivity is now expected to end at the ... patent for Cialis is valid and infringed by companies seeking ...
(Date:7/11/2017)... 11, 2017  The global market for liquid biopsy ... $394.1 million in 2016.  Although in early stages, the ... in particular as a result of the gradual shift ... recent introduction of a significant number of new liquid ... of tumor biomarkers to guide treatment decisions. ...
(Date:7/11/2017)... July 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... Drug Administration (FDA) has agreed to schedule an End-of-Phase ... IIb trial of its oral insulin capsule ORMD-0801 in ... trial met primary and secondary endpoints by indicating a ...
Breaking Medicine Technology: